BrainChild Bio: Valuation, Funding & Investors
BrainChild Bio is a clinical-stage biotechnology company developing CAR-T cell therapies for tumors in the central nervous system. Its kids-first platform prioritizes pediatric brain tumors, including diffuse intrinsic pontine glioma (DIPG), with plans to expand into additional pediatric and adult CNS tumor indications.
Leadership & Board
Key Executives
- Founder
- michael jensen
- Current Number of Employees
- 59
- Current LinkedIn Followers
- 5,623
Latest Estimated Valuation
- Total Amount Raised
- $116M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $116M
- Latest Funding Round
- Series A
Company Momentum
PositiveBrainChild Bio LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
BrainChild Bio had 59 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
BrainChild Bio had 5,623 followers as of November 9, 2026. The number of followers increased by 37 (0.66%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 09, 2026 | Series A | $116.00M | ― |
Similar Companies
A snapshot of private companies similar to BrainChild Bio, helping you discover and navigate related company profiles.








